A New Skin Product for Metabolic Syndrome Patients

A team of scientists at Rīga Stradiņš University (Latvia), one of the leading universities in the Baltic region, has developed a new product – facial cream for patients with metabolic syndrome.

Metabolic syndrome (MetS) is a group of risk factors – obesity, dyslipidemia, hypertension, and glucose intolerance. MetS is thought to increase the chances of type 2 diabetes, coronary heart disease and stroke, and nowadays it affects around 1/3 of the adult population worldwide. With an increase in obesity and sedentary lifestyle, the incidence rate is projected to rise even more. Therefore, MetS can be called a global epidemic.

MetS also has a negative impact on the skin, impairing its basic functions, such as skin immunity and the barrier function that protect from damage caused by endo- and exogenous factors and diseases. Studies have shown increased accumulation of oxidative stress and inflammatory markers in the skin of MetS patients. Altogether, it can lead to loss of moisture, premature skin aging, worsening of the existing skin conditions and even the development of new skin conditions. Prematurely aged skin, however, is associated with thinner skin, reduced elasticity and smoothness and increased pigmentation.

It is, therefore, clear that therapy for patients with metabolic syndrome is a complex process and should also include appropriate skincare.

Innovation

While the current market offers various products for dealing with skin aging (dryness, scaling, wrinkles, etc.), none of these products possess all complex actions – skin regeneration, restoration of the barrier function, hydration and other properties – that are vitally important for people whose skin is affected by MetS.

To fill the gap in the market, RSU scientists have come up with an innovative cream composition that combines a strong antioxidant property, natural skin lipid barrier restoration property, as well as moisturizing, anti-inflammatory and rejuvenating properties. It means that many of the skin problems of MetS patients might be resolved or at least significantly improved by means of this single cream. In combination with the baseline therapy of MetS, it can become a valuable addition in the treatment of some of the most visible and annoying aspects of MetS.

Research has demonstrated that the cream performs complex actions in patients with MetS:

• Promotes skin turgor and hydration;
• Restores elasticity and serves as smooth skin relief;
• Lessens pigmentation;
• Decreases inflammation manifestations.

• Regulatory status in EU: Medical device
• Regulatory status in USA: Cosmetic
• Patent Status:EP3439616 A4 
• Offer: License, development partnership